Immunotherapy in Lung Cancer: A New Age in Cancer Treatment

Corrales, Luis; Scilla, Katherine A.; Caglevic, Christian; Miller, Kimberly P.; Oliveira, J.; Rolfo, Christian

doi:10.1007/978-3-030-02505-2_3

Cited by 52 publications

(39 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Avelumab was FDA-approved in March 2017. The efficacy of avelumab for the treatment of advanced NSCLC is under investigation in several clinical trials [58,59].…”

Section: Programmed Cell Death Protein-1 (Pd-1)/programmed Death-lmentioning

confidence: 99%

Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)

Hsu

Jablons

Yang

et al. 2019

IJMS

137

100

View full text Add to dashboard Cite

The epidermal growth factor receptor (EGFR) pathway is a well-studied oncogenic pathway in human non-small cell lung cancer (NSCLC). A subset of advanced NSCLC patients (15–55%) have EGFR-driven mutations and benefit from treatment with EGFR-tyrosine kinase inhibitors (TKIs). Immune checkpoint inhibitors (ICIs) targeting the PD-1/PDL-1 axis are a new anti-cancer therapy for metastatic NSCLC. The anti-PD-1/PDL-1 ICIs showed promising efficacy (~30% response rate) and improved the survival of patients with metastatic NSCLC, but the role of anti-PD-1/PDL-1 ICIs for EGFR mutant NSCLC is not clear. YAP (yes-associated protein) is the main mediator of the Hippo pathway and has been identified as promoting cancer progression, drug resistance, and metastasis in NSCLC. Here, we review recent studies that examined the correlation between the EGFR, YAP pathways, and PD-L1 and demonstrate the mechanism by which EGFR and YAP regulate PD-L1 expression in human NSCLC. About 50% of EGFR mutant NSCLC patients acquire resistance to EGFR-TKIs without known targetable secondary mutations. Targeting YAP therapy is suggested as a potential treatment for NSCLC with acquired resistance to EGFR-TKIs. Future work should focus on the efficacy of YAP inhibitors in combination with immune checkpoint PD-L1/PD-1 blockade in EGFR mutant NSCLC without targetable resistant mutations.

show abstract

“…Avelumab was FDA-approved in March 2017. The efficacy of avelumab for the treatment of advanced NSCLC is under investigation in several clinical trials [58,59].…”

Section: Programmed Cell Death Protein-1 (Pd-1)/programmed Death-lmentioning

confidence: 99%

Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)

Hsu

Jablons

Yang

et al. 2019

IJMS

137

100

View full text Add to dashboard Cite

show abstract

“…Currently, there are two main types of antibodies targeting CTLA-4: Ipilimumab and tremelimumab ( 23 , 24 ). Ipilimumab has been approved by the U.S. Food and Drug Administration (FDA) as the first ICI for advanced melanoma based on several clinical trials, despite poor results in lung cancer ( 25 ). A randomized phase III trial demonstrated that ipilimumab in combination with chemotherapy did not markedly improve OS compared with chemotherapy alone in the first-line treatment for patients with advanced squamous NSCLC ( 26 ).…”

Section: Overview Of Immunotherapy In Non-small Cell Lung Cancermentioning

confidence: 99%

Biomarkers of immunotherapy in non‑small cell lung cancer (Review)

Wang

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

Immunotherapy has markedly improved the survival rate of patients with non-small cell lung cancer (NSCLC) and has introduced a new era in lung cancer treatment. However, not all patients with lung cancer benefit from checkpoint blockade, and some suffer from notable immunotoxicities. Thus, it is crucial to identify potential biomarkers suitable for screening the population that may benefit from immunotherapy. Based on the current clinical trials, the aim of the present study was to review the biomarkers for immune checkpoint inhibition, as well as other effective, invalid and hyperprogression markers that may have the potential to better predict responders to immunotherapy among patients with NSCLC. All these biomarkers may be incorporated into the predictive utility of bio-score systems and decision-making algorithms, to better guide the application of immunotherapy in the clinical setting. Contents 1. Introduction 2. Overview of immunotherapy in non-small cell lung cancer 3. Predictors of immunotherapy 4. Conclusions and future perspectives

show abstract

“…In NSCLC, the use of anti-PD-L1/PD-1 therapy is clinically approved [37], where PD-L1 positive patients have been showing great responses. Nevertheless, studies involving therapies targeting other immune checkpoint molecules in NSCLC, such as anti-CTLA-4 antibodies, have shown more disappointing results [40]. Importantly, the use of immunotherapy in pancreatic cancer has so far resulted in limited clinical success, and therefore it is not yet included in the clinical guidelines.…”

Section: Targeting Mutant Kras-driven Effects That Shape the Cancer-imentioning

confidence: 99%

Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors

Carvalho

Machado

Martins

et al. 2019

Cancers

View full text Add to dashboard Cite

Current evidence strongly suggests that cancer cells depend on the microenvironment in order to thrive. In fact, signals from the surrounding tumor microenvironment are crucial for cancer cells´aggressiveness, altering their expression profile and favoring their metastatic potential. As such, targeting the tumor microenvironment to impair cancer progression became an attractive therapeutic option. Interestingly, it has been shown that oncogenic KRAS signaling promotes a pro-tumorigenic microenvironment, and the associated crosstalk alters the expression profile of cancer cells. These findings award KRAS a key role in controlling the interactions between cancer cells and the microenvironment, granting cancer a poor prognosis. Given the lack of effective approaches to target KRAS itself or its downstream effectors in the clinic, exploring such interactions may open new perspectives on possible therapeutic strategies to hinder mutant KRAS tumors. This review highlights those communications and their implications for the development of effective therapies or to provide insights regarding response to existing regimens.

show abstract

Immunotherapy in Lung Cancer: A New Age in Cancer Treatment

Cited by 52 publications

References 57 publications

Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)

Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)

Biomarkers of immunotherapy in non‑small cell lung cancer (Review)

Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors

Contact Info

Product

Resources

About